GlassScriptPhysician profile
Richard Frederick Kutner
NPI 1043267008
$602.25
in general payments reported to CMS, 2019-2025
10 companies · $53.20 in 2025
The $53.20 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $78.37 · 2022: $19.57 · 2023: $49.74 · 2024: $84.76 · 2025: $53.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $187.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $167.33 | 2019-2025 | Dyanavel Xr |
| Shire North American Group INC | $136.18 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.76 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $50.52 | 2024 | Qelbree |
| Corium, LLC | $36.57 | 2022-2023 | Azstarys |
| Vertical Pharmaceuticals, LLC | $36.19 | 2020 | |
| Ironshore Pharmaceuticals INC. | $35.76 | 2023-2024 | Jornay Pm |
| Alkermes, INC. | $25.84 | 2025 | Aristada, Lybalvi |
| Abbvie INC. | $18.48 | 2024 | |
| Janssen Pharmaceuticals, INC | $13.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Kutner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.